103 related articles for article (PubMed ID: 20425112)
1. Analysis of copy number variations of BS69 in multiple types of hematological malignancies.
Yang H; Zhang C; Zhao X; Wu Q; Fu X; Yu B; Shao Y; Guan M; Zhang W; Wan J; Huang X
Ann Hematol; 2010 Oct; 89(10):959-64. PubMed ID: 20425112
[TBL] [Abstract][Full Text] [Related]
2. Examination of copy number variations of CHST9 in multiple types of hematologic malignancies.
Zhao X; Wu Q; Fu X; Yu B; Shao Y; Yang H; Guan M; Huang X; Zhang W; Wan J
Cancer Genet Cytogenet; 2010 Dec; 203(2):176-9. PubMed ID: 21156230
[TBL] [Abstract][Full Text] [Related]
3. Copy number variations of EphA3 are associated with multiple types of hematologic malignancies.
Guan M; Liu L; Zhao X; Wu Q; Yu B; Shao Y; Yang H; Fu X; Wan J; Zhang W
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):50-3. PubMed ID: 21454190
[TBL] [Abstract][Full Text] [Related]
4. The association between the copy-number variations of ZMAT4 and hematological malignancy.
Wan J; Gao Y; Zhao X; Wu Q; Fu X; Shao Y; Yang H; Guan M; Yu B; Zhang W
Hematology; 2011 Jan; 16(1):20-3. PubMed ID: 21269563
[TBL] [Abstract][Full Text] [Related]
5. Investigation of copy-number variations of C8orf4 in hematological malignancies.
Zhang J; Gao Y; Zhao X; Guan M; Zhang W; Wan J; Yu B
Med Oncol; 2011 Dec; 28 Suppl 1():S647-52. PubMed ID: 20878554
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
7. Patterns of hematological malignancies in Chernobyl clean-up workers (1996-2005).
Gluzman D; Imamura N; Sklyarenko L; Nadgornaya V; Zavelevich M; Machilo V
Exp Oncol; 2006 Mar; 28(1):60-3. PubMed ID: 16614710
[TBL] [Abstract][Full Text] [Related]
8. Expression and functional significance of osteocalcin splicing in disease progression of hematological malignancies.
Wihlidal P; Varga F; Pfeilstöcker M; Karlic H
Leuk Res; 2006 Oct; 30(10):1241-8. PubMed ID: 16387359
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
10. Integrative oncogenomic analysis of microarray data in hematologic malignancies.
Martínez-Climent JA; Fontan L; Fresquet V; Robles E; Ortiz M; Rubio A
Methods Mol Biol; 2010; 576():231-77. PubMed ID: 19882266
[TBL] [Abstract][Full Text] [Related]
11. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
12. Replication errors in hematological neoplasias: genomic instability in progression of disease is different among different types of leukemia.
Ohyashiki JH; Ohyashiki K; Aizawa S; Kawakubo K; Shimamoto T; Iwama H; Hayashi S; Toyama K
Clin Cancer Res; 1996 Sep; 2(9):1583-9. PubMed ID: 9816337
[TBL] [Abstract][Full Text] [Related]
13. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: Hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis.
Sari I; Altuntas F; Hacioglu S; Kocyigit I; Sevinc A; Sacar S; Deniz K; Alp E; Eser B; Yildiz O; Kaynar L; Unal A; Cetin M
Am J Hematol; 2008 Apr; 83(4):334-9. PubMed ID: 18069671
[TBL] [Abstract][Full Text] [Related]
14. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells.
de Lange P; Segeren CM; Koper JW; Wiemer E; Sonneveld P; Brinkmann AO; White A; Brogan IJ; de Jong FH; Lamberts SW
Cancer Res; 2001 May; 61(10):3937-41. PubMed ID: 11358809
[TBL] [Abstract][Full Text] [Related]
15. Marker chromosomes are a significant mechanism of high-level RUNX1 gene amplification in hematologic malignancies.
Moosavi SA; Sanchez J; Adeyinka A
Cancer Genet Cytogenet; 2009 Feb; 189(1):24-8. PubMed ID: 19167608
[TBL] [Abstract][Full Text] [Related]
16. Breakpoint differentiation in chromosomal aberrations of hematological malignancies: Identification of 33 previously unrecorded breakpoints.
Heller A; Loncarevic IF; Glaser M; Gebhart E; Trautmann U; Claussen U; Liehr T
Int J Oncol; 2004 Jan; 24(1):127-36. PubMed ID: 14654949
[TBL] [Abstract][Full Text] [Related]
17. Hematological malignancies: role of miRNAs and their in silico aspects.
Omer A; Yadav NK; Singh P; Singh RK
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1121-33. PubMed ID: 24053209
[TBL] [Abstract][Full Text] [Related]
18. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
[TBL] [Abstract][Full Text] [Related]
19. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.
Zhang SJ; Shi JY; Li JY
Leuk Res; 2009 Aug; 33(8):1141-3. PubMed ID: 19304323
[TBL] [Abstract][Full Text] [Related]
20. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
